Assessment of the concentration of selected metalloproteinases (MMP-2, MMP-3, MMP-9 and MMP-13) in patients with ulcers as a complication of type 2 diabetes

Daria Kupczyk¹, Rafał Bilski¹, Renata Studzińska², Alina Woźniak¹

¹Department of Medical Biology and Biochemistry Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
²Department of Organic Chemistry Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland

Adv Dermatol Allergol
DOI: https://doi.org/10.5114/ada.2020.100737

Abstract

Introduction: Impaired chronic wound healing is a great challenge for modern medicine. This process causes ulceration especially in the course of diseases such as type II diabetes mellitus.

Aim: This study assesses the concentration of selected matrix metalloproteinases in the example of metalloproteinase 2, 3, 9, 13 in patients with impaired healing of chronic wounds as a complication of type 2 diabetes.

Material and methods: Nineteen people took part in the assessment of wound healing in patients with type 2 diabetes. The control group consisted of 21 healthy people. In the blood serum the concentration of MMP-2, MMP-3, MMP-9 and MMP-13 was determined.

Results: The concentrations of MMP-2 and MMP-3 in the group of patients with ulcers were significantly higher (61% and 84% accordingly) compared to those in the control group without chronic wounds. No statistically significant differences in MMP-9 and MMP-13 concentrations were observed between the study and control groups.

Conclusions: The increase in MMP-2 concentration, which is particularly active in the degradation of type IV collagen, which is the main component of the basal membranes, in patients with type 2 diabetes may impede and delay the healing of chronic wounds and thus contribute to the intensification of vascular complications. In turn, the increase in MMP-3 concentration, which plays a significant role in vascular diseases, in patients with type 2 diabetes may lead to intensification of atherosclerotic changes involving the arteries of the lower extremities and ulceration.

Key words: matrix metalloproteinases, type 2 diabetes, complications of type 2 diabetes, impaired wound healing, ulcers.

Introduction

Diabetes is one of the most common metabolic disorders. The number of diabetics is constantly increasing. It is estimated that in 2025 it will reach 333 million [1]. Genetic, environmental and lifestyle factors underlie its development. The cause of type 2 diabetes is impaired insulin secretion and function, leading to the development of insulin resistance [2, 3]. The group of risk factors responsible for its occurrence includes obesity, improper diet, low physical activity, genetic burden or age above 45 years [4]. In type 2 diabetes, as a result of elevated glucose levels, in addition to the occurrence of acute metabolic disorders, there are complications in the large and small vessels of a micro- and macroangiopathy nature [5, 6]. One of the most serious is diabetic foot syndrome. During the whole life of diabetics, there is increasing risk of developing ulceration and amputation of the lower extremities, which in most cases is preceded by ulceration, which is easily infected and leads to hospitalization [7–10]. Diabetic neuropathy and ischemia of the lower extremities are the most important etiological factors of foot ulcers. In patients, sensory nerve fibers are damaged, leading to the inability to feel pain. As a result, even smaller injuries or cuts, without giving any pain, can...
remain unnoticed for a long time. In turn, as a result of atherosclerotic changes that arise in the vessels of the lower extremities, ischemia occurs, causing a deterioration of the healing process, fighting infection or hindering the penetration of the antibiotic to the site of infection [1]. In addition, T-lymphocyte dysfunction and immune disorders impede the healing process, thereby increasing the risk of limb amputation in diabetic patients with foot ulceration [11, 12].

Factors that may promote diabetes and are involved in the pathogenesis of associated vascular changes and complications include matrix metalloproteinases. They constitute a group of 20 (approximately) zinc-dependent proteolytic enzymes, the production of which takes place in most connective tissue cells, macrophages, leukocytes, vascular endothelial cells or cancer cells [13]. Most members of the metalloproteinase family are organized into three main and distinct domains: the N-terminal propeptide, the catalytic domain, and the hemopexin domain at the carboxy terminus of the molecule. Matrix metalloproteinases include: collagenase, matrilysin, stromelysin, gelatinase, membrane metalloproteinases and others, which have not been assigned to any of the listed groups [14]. Their main role is the degradation of extracellular matrix proteins, i.e. collagen, laminin, fibronectin and proteoglycans, which promotes cell migration and release of growth factors acting on the cells. Substrates of matrix metalloproteinases include cytokines, chemokines, growth factors and hormones, which may be activated or inactivated or transformed into products with new biological activity due to proteolytic processes [15]. Metalloproteinases are involved in the regulation of embryogenesis, control of angiogenesis, immunological processes as well as in wound healing under physiological conditions [16, 17]. However, excessive expression of the same enzymes causes that they are also involved in numerous pathological processes, leading to degradation of the extracellular matrix [18]. Excessive activation of metalloproteinases has observed in atherosclerosis or cardiovascular diseases. They also play an important role in the development and severity of vascular complications in patients with type 2 diabetes [19].

The above information shows that the care of patients with difficult to heal wounds and ulcers, which are a complication of type 2 diabetes, should be interdisciplinary. Metalloproteinases, through their ability to degrade insulin, can exacerbate the disease. The mechanism of development of these complications is currently the subject of our research.

**Aim**

The aim of this study is to assess the concentration of selected matrix metalloproteinases in patients with ulcers that are a complication of type 2 diabetes.

**Material and methods**

The study included a group of 19 people, including 10 women and 9 men, aged 68–87. The study group consisted of patients from a specialist surgery whose activities include surgical nursing and chronic wound treatment. Patients with ulceration in the foot and lower leg area, a complication of type 2 diabetes, who gave written consent for the examination, were qualified for the study. Exclusion criteria for the study included: no written consent, cancer, concomitant inflammatory diseases of the osteoarticular system, heart disease, dementia, Alzheimer’s and Parkinson’s disease. Patients who came to the office were under the specialist care of medical staff, because the process of chronic wound and ulcer treatment is long and requires taking a number of actions, such as wound development, the use of total contact cast (TCC) fixations, negative pressure wound therapy (NPWT) or the use of devices and devices enabling fast and accurate transdermal measurement of oxygen partial pressure (TcpO2) or measurement of systolic blood pressure on the fingers of the lower and upper limbs. The control group consisted of 21 healthy people aged between 32 and 62 (12 women and 9 men). The control group was selected from people without chronic diseases, without signs of inflammation or neurodegenerative processes that are characteristic for old age.

The material for biochemical tests was venous blood collected in the amount of approx. 5 ml from the ulnar vein into tubes devoid of anticoagulant. Blood was collected in the morning. Then the collected material was transported to the Medical Biology and Biochemistry Department of the Collegium Medicum in Bydgoszcz at the Nicolaus Copernicus University in Torun. The study was permitted by the bioethics committee of Nicolaus Copernicus University in Torun (permission number KB 344/2018). Serum was obtained from blood collected in tubes without anticoagulant by centrifuging the material for 5 min at 5000 × g, and then transferred to Eppendorf tubes and frozen at −80°C. The serum prepared in this manner was stored for the determination of metalloproteinase 2 (MMP-2), metalloproteinase 3 (MMP-3), metalloproteinase 9 (MMP-9) and metalloproteinase 13 (MMP-13). The analysis of selected metalloproteinases was carried out by the ELISA method using Cloud Clone Corp. kits. (MMP-2 cat No: SEA100Hu; MMP-3 cat No: SEA101Hu; MMP-9 cat No: SEA553Hu; MMP-13 cat No: SEAO99Hu).

**Statistical analysis**

Statistical analysis of biochemical parameters was performed using the Statistica 10.0 program. The distribution normality was first tested using the Shapiro-Wilk test. The tested parameters met the criteria of normal distribution. The T test for independent variables was used for further analysis. Next, Spearman’s R correlation analysis was performed.
Assessment of the concentration of selected metalloproteinases (MMP-2, MMP-3, MMP-9 and MMP-13) in patients with ulcers as a complication of type 2 diabetes

Results
The average concentration of MMP-2 in the serum of subjects in the study group was 61% higher than in the control group (Figure 1). The level of statistical significance was \( p = 0.046 \). A statistically significant difference in MMP-3 concentration between groups was also observed. MMP-3 concentration in the study group was 84% higher than in the control group (\( p = 0.023 \)) (Figure 2). There was no statistically significant difference in MMP-9 concentration between the study and control group (\( p = 0.598 \)). There was also no statistically significant difference in MMP-13 concentration between the study and control group (\( p = 0.106 \)) (Table 1). A statistically significant positive correlation (\( r = 0.60, p = 0.02 \)) between concentrations of MMP-2 and MMP-3 was observed (Figure 3).

Discussion
Type 2 diabetes, in addition to factors such as hypertension, abdominal obesity, lipid disorders, age, smok-

Table 1. Presentation of average concentration values of metalloproteinases in the study and control groups

| Parameter | Study group (n = 19) | Control group (n = 21) | \( P \)-value |
|-----------|---------------------|-----------------------|--------------|
|           | Mean | Standard deviation | Mean | Standard deviation |        |
| MMP-2 [pg/ml] | 7463.9 | 5275.6 | 4634.3 | 3302.1 | 0.046 |
| MMP-3 [pg/ml] | 3745.0 | 2723.6 | 2030.6 | 1582.4 | 0.023 |
| MMP-9 [pg/ml] | 2289.4 | 355.6 | 2461.1 | 404.2 | 0.598 |
| MMP-13 [pg/ml] | 829.9 | 1180.7 | 1171.3 | 1750.0 | 0.106 |
In relation to this collagen, MMP-2 and MMP-9 metalloproteinases show high substrate activity. They are present in the wall of blood vessels and come from T lymphocytes and smooth muscle cells. In addition, MMP-9 can also be produced by macrophages, mast cells, fibroblasts and endothelial cells. The effect of these metalloproteinases is not limited to degradation of type IV collagen, as they also affect the processes of apoptosis, cytokine release or maintaining tissue continuity [22, 23]. A major role is assigned to these metalloproteinases in the development of atherosclerosis, especially in the degradation of collagen, glycosaminoglycans and proteoglycans [24, 25]. Research from recent years also indicates that a group of matrix metalloproteinases belonging to type IV collagenases is involved in the development of autoimmune diseases such as type 1 diabetes, but also type 2 diabetes. Elevated serum glucose induces expression and activity of MMP-2 collagenase in endothelial cells and MMP-9 in macrophages [26]. Gharagozlan et al. found that the activity of MMP-2 and MMP-9 in the serum of patients with type 1 diabetes was significantly higher compared to the control group [27]. Similarly, Shiau et al. found that the concentration of both type IV collagenases is higher in diabetic patients without complications compared to the control group [28]. Experiments carried out by Maxwell et al. did not indicate an increase in MMP-2 plasma concentration in patients with type 1 diabetes, but they observed an increase in MMP-9 in these patients compared to the control group [29]. In turn, Prystupa et al. reported that the level of MMP-2 activity was reduced in patients with type 2 diabetes compared to the control group, while MMP-9 activity did not differ statistically from the control group [30].

Our studies also showed no statistically significant differences in MMP-9 activity in patients with ulcers that are a complication of type 2 diabetes compared to the control group. The concentration of MMP-9 for both patients and the control group was in a similar range (from 2289.41 to 2765.40 pg/ml for patients and from 2461.06 to 2866.4 pg/ml for the control group, respectively). In contrast, the concentration of MMP-2 observed in patients with ulcers was clearly higher and ranged from 2081.80 to 18 124.65 pg/ml, compared to the control group (617.25 to 14 936.15 pg/ml).

When selecting patients for the clinical trial, we tried to obtain a homogeneous group of patients only with ulcers that are a complication of type 2 diabetes, as additional disorders could affect the concentration of metalloproteinases in the blood serum. For example, when assessing MMP-9 concentration, the presence of hyperhomocysteinemia in patients should be taken into account, as high levels of this amino acid are reported to be one of the factors that increase MMP-9 levels. Moshal et al. demonstrated in their research the relationship between hyperhomocysteinemia and gene expression for MMP-9 in endothelial cells [30]. It can therefore be presumed that in patients with complications of type 2 diabetes, hyperhomocysteinemia may cause an increase in MMP-9 production in vascular endothelial cells. In addition, factors such as obesity or hypertriglyceridemia, among others, may increase MMP-9 activity in type 2 diabetes [31]. More importantly, in the context of the role of MMP-9, it seems that this metalloproteinase is important for maintaining the correct tone of the blood vessel wall [32]. In addition, Salonurmi et al. conducted an experiment on transgenic mice, based on which they verified the role of MMP-9 in wound healing. In these mice, a fragment of human DNA encoding TIMP-1 was placed in front of the promoter of the gene encoding MMP-9. As a result, TIMP-1 was expressed in transgenic mice in tissues in which wild mice were expressed. Studies on this type of mice have shown that the wound healing process resulting from sterile dorsal incisions is significantly delayed [32]. In turn, Frassing et al. found no effect of MMP-2 on wound healing in plasminogen-deficient mice [33]. Another metalloproteinase whose concentration was evaluated in this study is MMP-3, which belongs to the stromelysin group. It has high proteolytic activity. In addition to the hydrolysis of components of the extracellular matrix, it activates numerous zymogens of metalloproteinases (proMMP). Its presence is also necessary for the activation of MMP-1 [23, 34]. Amanzadeh et al. observed lower activity of MMP-3 in patients with macroalbuminuria in comparison with patients with microalbuminuria and normoalbuminuria. In addition, the research team found a positive correlation between glomerular filtration rate and MMP-3 activity in diabetic patients. On this basis, it can be concluded that MMP-3 may play a role in the pathogen-
Assessment of the concentration of selected metalloproteinases (MMP-2, MMP-3, MMP-9 and MMP-13) in patients with ulcers as a complication of type 2 diabetes

Metalloproteinases are involved in the pathogenesis of diabetic complications. They can also exacerbate the course of the disease. The degradation of basal membranes, components of the extracellular matrix dependent on metalloproteinases, underlies the development of diabetic complications.

Conclusions

Therefore, the research presented in this paper should be continued in order to collect and develop data for a larger study group.

Conflict of interest

The authors declare no conflict of interest.

References

1. Borissova AM, Shinkov A, Kovatcheva R, et al. Changes in the prevalence of diabetes mellitus in Bulgaria (2006-2012). Clin Med Insights Endocrinol Diabetes 2015; 8: 41-S.
2. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the patho-...
genius of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006; 29: 1130-9.

3. Del Prato S. Role of gluco-toxicity and lipotoxicity in the pathophysiology of type 2 diabetes mellitus and emerging treatment strategies. Diabet Med 2009; 26: 1185-92.

4. Tripathi BK, Srivastava AK. Diabetes mellitus: complications and therapeutics. Med Sci Monit 2006; 12: 130-52.

5. Genuith S, Eastman R, Kahn R, et al.; American Diabetes Association (2000). Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 2003; 26 Suppl 1: S28-32; Suppl 1: 27-31.

6. Jung KH, Chu K, Lee ST, et al. Risk of macrovascular complications in type 2 diabetes mellitus: endothelial microparticle profiles. Cerebrovasc Dis 2011; 31: 485-93.

7. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes JAMA 2005; 293: 217-28.

8. Lavery LA, Ashyr HR, van Houtum W, et al. Variation in the incidence and proportion of diabetes related amputations in minorities. Diabetes Care 1996; 19: 48-52.

9. Lavery LA, van Houtum W, Astry HR, et al. Diabetes-related lower extremity amputations disproportionately affect blacks and Mexican Americans. South Med J 1999; 92: 593-9.

10. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic foot ulcers: the role of endothelial dysfunction. Clin Sci 2005; 109: 143-59.

11. Flaman M, Placier S, Dubroca C, et al. Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension 2007; 50: 212-8.

12. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-39.

13. Fic P, Zakraicka I, Kurzepa J, Stepulak A. Metalloproteinaznye w miażdżycy naczyń krwionośnych. Post Hig Med Dosw 2011; 65: 16-27.

14. Blakytny R, Jude E. The molecular biology of chronic wounds and delayed healing in diabetes. Diabet Med 2006; 23: 594-608.

15. Haq M, Shaeii AE, Zeros EE, Rosemary AS. In vitro and in vivo matrix metalloproteinase production by pancreatic cancer cells and by distant organ. Int J Surg Invest 2000; 1: 459-65.

16. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus. FEMS Immunol Med Microbiol 1999; 26: 259-65.

17. Blaktytny R, Jude E. The molecular biology of chronic wounds and delayed healing in diabetes. Diabet Med 2006; 23: 594-608.

18. Salmela MT, Pender SI, Karrjainen-Lindsay ML, et al. Collagenase-1 (MMP-1), matrilysin-1 (MMP-7), and stromelysin-2 (MMP-10) are expressed by migrating enterocytes during intestinal wound healing. Scand J Gastroenterol 2004; 39: 1095-104.

19. Egeblad M, Werb Z. New functions for the matrix metalloproteinases In cancer progression. Nat Rev Cancer 2002; 2: 163-76.

20. Mittal R, Patel AP, Debs LH, et al. Intricate functions of matrix metalloproteinases in physiological and pathological conditions. J Cell Physiol 2016; 231: 2599-621.

21. Peeters SA, Engelen L, Buijs J, et al. EURODIAB Prospective Complications Study Group. Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study. Cardiovasc Diabetol 2015; 14: 31.

22. Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases: a statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23: 233-46.

23. Chattikij CW, Stenhower CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Acta Diabetologica 2013; 50: 907-10.

24. Yu Y, Koike T, Kitajima S, et al. Temporal and quantitative analysis of expression of metalloproteinases (MMPs) and
their endogenous inhibitors in atherosclerotic lesions. Histol Histopathol 2008; 23: 1503-16.
41. Newby AC. Dual role of matrix metalloproteinases (matrix-ins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005; 85: 1-31.
42. Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 2008; 28: 2108-14.
43. Busti C, Falcinelli E, Momi S, Gresele P. Matrix metalloproteinases and peripheral arterial disease. Intern Emerg Med 2010; 5: 13-25.
44. Kupczyk D, Bilski R, Przewięźlikowski A, et al. Concentration of proinflammatory cytokines in patients with ulcers as complications of type 2 diabetes mellitus. Adv Dermatol Allergol 2020. doi:10.5114/ada.2020.96702.
45. Słowiński-Żyłka D, Safranow K, Ciechanowski K. Późne produkty glikacji białek (AGE) – powstawanie, znaczenie patogeneetyczne, oznaczanie. Diabetol Pol 2001; 8: 281-21.